Sino Biological launches 4RISE wet-lab platform for AI-designed molecules
Sino Biological is promoting 4RISE™, an integrated wet-lab service designed to move AI-generated protein candidates from computational predictions to experimental evidence. The company says the platform combines high-throughput expression, target protein resources and validation of binding, development potential and biological function.
- 4RISE™ combines protein expression, target resources and experimental validation.
- XPressMAX™ can express proteins in about 3 hours, according to Sino Biological.
- The company says suitable workflows can deliver binding data in 3 days.
- The platform includes more than 20 developability and functional assays.
- Sino Biological says it has collaborated with more than 50 AI companies.
From AI predictions to laboratory evidence
AI can generate protein candidates quickly, but laboratory testing is still needed to assess whether those candidates can be expressed, bind their targets and deliver the intended biological properties. Sino Biological, Inc., which is listed on the Shenzhen Stock Exchange as 301047.SZ, said 4RISE™ addresses this gap through an integrated set of wet-lab capabilities.
The platform is structured around four capabilities: rapid expression, in-depth analysis, seamless support and empirical experience. The company says this approach is intended to help researchers identify promising candidates and continue AI-driven design cycles using experimental results rather than computational predictions alone.
Rapid expression and high-throughput binding data
For rapid expression, 4RISE™ uses the XPressMAX™ cell-free protein synthesis system. According to Sino Biological, the system can express proteins in about 3 hours and achieves success rates above 99% in established workflows.
The company also offers more than 11,000 ready-to-use target proteins. Combined with high-throughput SPR and BLI analysis, suitable workflows can provide AI-ready binding data in 3 days, according to Sino Biological. Structured data and API access are intended to support later retrieval, analysis and optimization.
This setup could help research teams shorten the path from sequence screening to initial binding results. The company's description focuses on speed in expression, screening and data delivery, while leaving the selection of suitable workflows to the specific molecule and target.
Validation goes beyond target binding
4RISE™ is designed to evaluate more than binding and kinetic characteristics. Sino Biological says the platform includes more than 20 developability assays, along with molecular and cell-based functional tests that can be used to assess candidate quality and biological activity.
The service combines cell-free and mammalian expression platforms to support different molecule types and expression requirements. Its integrated offering also covers an internal target protein portfolio, antibody production, binding characterization, developability assessment and functional validation.
Sino Biological said it has experience supporting AI-designed miniproteins, VHH, scFv, Fab, IgG, enzymes and cytokines. The company also said it has worked with more than 50 AI companies, giving it practical wet-lab experience in validating AI-designed molecules.
For researchers, the announcement points to a service aimed at converting AI-generated sequences into experimental datasets that can guide candidate evaluation and subsequent design decisions. Sino Biological's US managing director, Dr. Rob Burgess, said AI-driven discovery requires reliable experimental data in addition to computational predictions. The company directs potential users to its 4RISE™ wet-lab validation services.


